Acepodia

Focus: Acepodia is an early-stage oncology biotech specializing in antibody-cell conjugation (ACC) therapeutics, a novel modality combining antibodies with cellular payloads. Founded in 2020 and currently at Series C+ stage, the company is pre-revenue with a focused pipeline in solid tumors and rare immunological diseases.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES C +

Open Jobs

About Acepodia

AI assessmentNot Hiring

No open roles listed right now. Follow Acepodia to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ACE1702

Locally Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT04319757ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1

Help build intelligence for Acepodia

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering a novel modality (ACC therapy) with potential first-mover advantage in an emerging therapeutic class with limited competitive saturation
Early-stage company at Series C+ funding stage offers meaningful equity upside and the ability to shape platform development and organizational culture from inception
Focused oncology pipeline with clinical programs in Phase 1/2 allows deep technical specialization in mechanism development and early translational science

Watch Out For

Zero active job openings at time of analysis signals potential hiring freeze, capacity constraints, or recent completion of founding team assembly
Pre-revenue status with unfunded financials creates cash burn risk; Series C+ capital may be insufficient to fund 3+ years of clinical development without additional financing
Very early clinical stage (4 Phase 1 programs, 1 Phase 2) means minimal near-term value creation events; significant clinical and regulatory risk before meaningful catalysts

Generated by Claude from Acepodia's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ACE2016

Locally Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT06415487ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Phase 1

ACE1831

IgG4-Related Disease

Phase 1/2

Clinical Trials (2)

NCT07061938Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Phase 1/2

NCT05653271ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2020

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline